MAUREEN GENOV: Open Payments
NPI 1396368015 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 45 payments from 12 companies in 2025. Trend: 2023 $4,761 · 2024 $2,441 · 2025 $1,514
Food & beverage: $1,514
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $430 |
| AstraZeneca Pharmaceuticals LP | 5 | $233 |
| Optinose US, Inc. | 5 | $178 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $146 |
| Novartis Pharmaceuticals Corporation | 5 | $128 |
| Genentech USA, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $93 |
| GlaxoSmithKline, LLC. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| BioCryst US Sales Co., LLC | 1 | $31 |
Products named: DUPIXENT, TEZSPIRE, Xhance, NEFFY, Xolair, CUVITRU, Rhapsido, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
